Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$106.26 USD
+1.12 (1.07%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $106.29 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ZBH 106.26 +1.12(1.07%)
Will ZBH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZBH
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Other News for ZBH
Zimmer Biomet price target lowered by $5 at Truist, here's why
Stocks that would be impacted by an increase in tariffs if Trump wins - Barclays
Zimmer Biomet Holdings Moves Up In Market Cap Rank, Passing Cincinnati Financial
Zimmer Biomet price target lowered by $2 at Wells Fargo, here's why
Zimmer Biomet price target lowered by $5 at Canaccord, here's why